Login to Your Account

Cymabay gets FDA nod on plans for phase III gout drug trials

By Michael Fitzhugh
Staff Writer

Wednesday, January 20, 2016

Cymabay Therapeutics Inc. said the FDA has agreed to designs for a trio of pivotal phase III studies to test the company's oral, once-daily gout candidate, arhalofenate, with Uloric, a milestone that gives the company clarity that could help it launch the trials this year and secure a needed partner for the program as well.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription